Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021

Early Transmission Dynamics, Spread, and Genomic Characterization of SARS-CoV-2 in Panama

Danilo Franco1, Claudia Gonzalez1, Leyda E. Abrego1, Jean-Paul Carrera, Yamilka Diaz, Yaset Caicedo, Ambar Moreno, Oris Chavarria, Jessica Gondola, Marlene Castillo, Elimelec Valdespino, Melissa Gaitán, Jose Martínez-Mandiche, Lizbeth Hayer, Pablo Gonzalez, Carmen Lange, Yadira Molto, Dalis Mojica, Ruben Ramos, Maria Mastelari, Lizbeth Cerezo, Lourdes Moreno, Christl A. Donnelly, Juan Miguel Pascale, Nuno Rodrigues Faria, Sandra Lopez-VergesComments to Author , Alexander A. Martinez, and on behalf of Gorgas COVID19 team and Panama COVID19 Laboratory Network 3 -->
Author affiliations: Gorgas Memorial Institute of Health Studies, Panama City, Panama (D. Franco, C. Gonzalez, L.E. Abrego, J.-P. Carrera, Y. Diaz, A. Moreno, O. Chavarria, J. Gondola, M. Castillo, E. Valdespino, M. Gaitán, J. Martínez-Mandiche, D. Mojica, R. Ramos, J.M. Pascale, S. Lopez-Verges, A.A. Martinez); Universidad de Panama, Panama City (D. Franco, C. Gonzalez, L.E. Abrego, J.M. Pascale, S. Lopez-Verges, A.A. Martinez); Ministry of Health of Panama, Panama City (L. Hayer, P. Gonzalez, C. Lange, Y. Molto, M. Mastelari, L. Cerezo, L. Moreno); University of Oxford, Oxford, UK (J.-P. Carrera, C.A. Donnelly, N.R. Faria); Fundación Valle del Lili, Cali, Colombia (Y. Caicedo); Imperial College, London, UK (C.A. Donnelly, N.R. Faria)

Cite This Article


We report an epidemiologic analysis of 4,210 cases of infection with severe acute respiratory syndrome coronavirus 2 and genetic analysis of 313 new near-complete virus genomes in Panama during March 9–April 16, 2020. Although containment measures reduced R0 and Rt, they did not interrupt virus spread in the country.

Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in December 2019 in Wuhan, China (1,2). Of ≈23 million confirmed cases worldwide, as of October 20, 2020, a total of 28% (>6 million) had been reported in Latin America. SARS-CoV-2 was first reported in this region in São Paulo, Brazil, on February 25, 2020 (3).

In Panama, the first confirmed COVID-19 case was reported on March 9, 2020. Although Panama rapidly implemented disease control strategies, it is among the countries in Latin America with the highest cumulative rates of incidence and death (4). To elucidate the transmission and spread of SARS-CoV-2 in the region, we analyzed epidemiologic surveillance data and newly generated genetic data from Panama.

The Study

To perform molecular detection of SARS-CoV-2, the Panama Ministry of Health implemented a surveillance program on January 20, 2020. The National Committee on Bioethics of Research of Panama approved protocol EC-CNBI-202–04–46.

We evaluated the early transmission dynamics of COVID-19 in Panama for the first 62 days of the epidemic (February 15–April 16, 2020) based on reported dates of symptom onset. We estimated the daily growth rate, doubling time, and basic (R0) and time-varying (Rt) effective reproduction numbers. We performed genome amplification and sequencing according to ARTIC Network protocol ( for Illumina Sequencing ( (5). Details of epidemic parameters, sequencing, and genome analysis are described in Appendix 2.

Figure 1

Epidemic curve of SARS-CoV-2 cases in Panama showing daily incidence of confirmed imported and local infections detected through April 16, 2020, with symptom onset during February 15–April 13, 2020. Gray shaded area indicates time period during which nonpharmaceutical interventions measures were initiated. Inset at top right shows the time-varying effective reproduction number (Rt) for a time frame of 45 days (x-axis); dark gray shading indicates 95% CI, and dashed line indicates threshold value Rt = 1. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Figure 1. Epidemic curve of SARS-CoV-2 cases in Panama showing daily incidence of confirmed imported and local infections detected through April 16, 2020, with symptom onset during February 15–April 13, 2020. Gray...

A total of 18,559 suspected cases of COVID-19 had been investigated in Panama by April 16. Of these, 4,210 (22.7%) patients tested positive for SARS-CoV-2 infection by qualitative reverse transcription PCR. The first confirmed case, on March 9, corresponded to a patient who had arrived in Panama from Spain on March 8 and had exhibited symptoms beginning on March 6. The first case not related to travel was confirmed after the death on March 7 of a patient in whom symptoms first appeared on February 22. Epidemiologic investigation showed that the date of onset of symptoms for the earliest local case related to that fatal case dates back to February 15, 2020 (Figure 1). In most locally detected cases, patients had mild disease symptoms (Appendix 2 Figure 1, panel A).

By April 16, a total of 341 patients had been hospitalized (77 at time of diagnosis confirmation) and 116 had died (31 by time of diagnosis confirmation) (Appendix 2 Figure 1, panels B, C). The highest proportion of confirmed cases was observed in the 20–59 year age group (Appendix 2 Figure 2, panel A). A higher proportion (55.3%) of patients tested were female, but among those with positive results, 1.45 times more were male (Appendix 2 Figure 2, panel B). A rapid growth rate of 0.13 cases/day (Appendix 2 Figure 3, panel A) and a short doubling time were observed during the early stages of the epidemic; doubling time increased over the study period (Appendix 2 Figure 3, panel B). We estimated an R0 for SARS-CoV-2 in Panama of 2.22 (95% CI 2.08–2.37).

Panama was the 11th country in Latin America to report SARS-CoV-2 and implemented epidemic control strategies rapidly compared with other countries in the region (Appendix 2 Figure 4). After the first confirmed case (March 9), school closures were implemented within 1 day, social distancing measures within 6 days, and 24-hour stay-at-home curfew within 14 days. Over the course of the next 17 days, Rt dropped to 1.08 (95% Cl 1.00−1.17) (Appendix 2 Table 1, Figure 3, panel C). However, until April 16, Panama remained the country in Central America with the highest proportional number of cases and fatalities (Appendix 2 Figure 5).

Figure 2

Genetic diversity of SARS-CoV-2 in Panama. A) Bayesian maximum clade credibility tree of 1,261 SARS-CoV-2 sequences: 133 from Panama; 492 from North or South America (443 genomes are from Brazil, 41 from the United States, 7 from Chile, 6 from Mexico, 3 from Argentina, 1 from Peru, and 1 from Canada); and 636 are from other locations. Posterior density estimates of time of the most recent common ancestor of each lineage with local transmission are shown in their branches. B) Distribution of lineages among regions in Panama. C) Distribution of lineages by channel of exposure detected by the surveillance system. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Figure 2. Genetic diversity of SARS-CoV-2 in Panama. A) Bayesian maximum clade credibility tree of 1,261 SARS-CoV-2 sequences: 133 from Panama; 492 from North or South America (443 genomes are from Brazil,...

To determine the diversity of SARS-CoV-2 in Panama and Latin America, we generated SARS-CoV-2 genomes from 313 patients, representing 7.4% of the total confirmed cases by April 16, 2020 (Appendix 2 Figure 6, panel A). We obtained complete genome coverage for samples using reverse transcription PCR cycle threshold values <25 (Appendix 2 Figure 6, panel B) and found circulation of >10 virus lineages (Figure 2, panel A; Appendix 2 Figure 7) (6). The most frequently identified was A.2 (71.2%), followed by B.1 (16.7%) and A.1 (3.5%), in contrast to other studies in Latin America, where B-like lineages largely predominate (7,8). Lineages A.3, B, and B.1.5 were identified in 79 cases detected early on in the epidemic, 11 (13.9%) of the cases imported (Figure 2, panel A; Appendix 2 Figure 7). Lineage A.2 was found in 51 patients; 4 (7.8%) belonged to a cluster (Appendix 2 Table 2) from a school outbreak associated with the first detected local case and 9 (17.6%) were police officers (Figure 2, panel C).

Phylogenetic analysis identified 3 main virus lineages (Figure 2). Lineage A.2.1/19B (n = 60; posterior support = 0.69; C12815T) comprised 54.3% of the sequenced cases in the study (Appendix 2 Figure 8, panel A); lineage B.1/20A (n = 15; posterior support = 0.97; G26143A) and lineage A.3/19B (n = 12; posterior support = 1.00; C3177T, T26729C) was third. Molecular clock estimates of the time to most recent common ancestor calculated from lineage A.2.1, made up just of cases with local transmission, placed the median time of mutation during February 19–March 9, 2020, just 2 weeks before the first COVID-19 case was confirmed, and in line with the time of onset of symptoms of the first case of local transmission (Figures 1, 2).

Central and western Panama had more diverse lineage distributions (Figure 2, panel B). These regions encompass the capital and its surroundings, where more than 50% of the national population lives and the main international airport is located. Lineage A.2.1 was found in all regions across the country with no obvious spatial pattern; according to a global analysis of SARS-CoV-2 lineages (, this lineage is composed of sequences predominantly from Panama. We also found that the spike glycoprotein variants D614 and G614 (9,10) were cocirculating early in the epidemic among all the regions analyzed and were comprised of multiple lineages (Appendix 2 Figure 8, panel B), but the G614 variant potentially associated with infectivity (9) was detected in only 18.8% of the sequenced cases (Appendix 2 Figure 8, panel C).


Epidemiologic evidence suggested cryptic circulation of SARS-CoV-2 in Panama with a probable introduction during early February. A high median transmission potential of SARS-CoV-2 was estimated at R0 = 2.22 (2.08–2.37), similar to estimates from China, Brazil, and Europe (1113). Rt rapidly dropped to 1.08 after implementation of control strategies.

Phylogenetic analysis detected circulation of >10 virus lineages, although the number of detected lineages could be underestimated because we did not sequence each positive case and there is a possibility of uncommon undetected lineages due to sample bias. Most of the lineages associated with imported cases (A.1, A.3, B, B.1, B.2.1) were detected and transmission controlled through active contact tracing. However, we detected early transmission of the lineage A.2.1/19B, which was introduced into the country >3 weeks before the first detected case. This lineage rapidly became widespread in Panama.

We conjecture that efforts to identify early suspected cases, which focused mainly in symptomatic travelers returning from China, precluded the opportunity to detect earlier cases imported from Europe and the United States, where the virus was already circulating at that time (11,14,15). Moreover, undetected early transmission occurring before control measures were implemented could help to explain the widespread distribution of SARS-CoV-2 across Panama.

Our findings on growth rates and Rt show that mitigation measures undertaken shortly after the first reported case in March helped to reduce virus transmission. Measures such as active contact tracing and isolation, social distancing, and quarantine targeted to regions where active transmission clusters are found will help to effectively control the spread of SARS-CoV-2 in Panama.

Mr. Franco is responsible for respiratory virus surveillance and SARS-CoV-2 molecular diagnosis in the Department of Research in Virology and Biotechnology at the Gorgas Memorial Institute of Health Studies in Panama. His research is focused on epidemiological and genetic analysis of respiratory viruses circulating in Panama.



We thank the Gorgas administration and general services for their support and extra work during the COVID-19 response. We also thank all the health institutions from MINSA, CSS, and private hospitals. We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database on which this research is based Appendix 1 Table 2).

A.A.M., J.M.P., S.L.V., and L.E.A. are members of the Sistema Nacional de Investigación from SENACYT, Panama. N.R.F. was supported by Wellcome Trust and Royal Society (204311/Z/16/Z) and by Medical Research Council-São Paulo Research Foundation’s Center for Arbovirus Discovery, Diagnosis, Genomics and Epidemiology partnership award (MR/S0195/1 and FAPESP 18/14389-0).



  1. Li  Q, Guan  X, Wu  P, Wang  X, Zhou  L, Tong  Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199207. DOIPubMed
  2. Zhu  N, Zhang  D, Wang  W, Li  X, Yang  B, Song  J, et al.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:72733. DOIPubMed
  3. Jesus  JG, Sacchi  C, Candido  DDS, Claro  IM, Sales  FCS, Manuli  ER, et al. Importation and early local transmission of COVID-19 in Brazil, 2020. Rev Inst Med Trop São Paulo. 2020;62:e30. DOIPubMed
  4. World Health Organization. Coronavirus disease (COVID-19) pandemic [cited ___]
  5. Quick  J, Grubaugh  ND, Pullan  ST, Claro  IM, Smith  AD, Gangavarapu  K, et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. Nat Protoc 2017;12;1261–76. DOIPubMed
  6. Rambaut  A, Holmes  EC, O’Toole  Á, Hill  V, McCrone  JT, Ruis  C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5:1403–7. DOIPubMed
  7. Laiton-Donato K, Villabona Arenas CJ, Usme Ciro JA, Franco Munoz C, Alvarez-Diaz DA, Villabona-Arenas LS, et al. Genomic epidemiology of SARS-CoV-2 in Colombia. medRxiv 2020;2020.06.26.20135715.
  8. Candido  DS, Claro  IM, de Jesus  JG, Souza  WM, Moreira  FRR, Dellicour  S, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science. 2020;369:1255–60. DOIPubMed
  9. Korber  B, Fischer  WM, Gnanakaran  S, Yoon  H, Theiler  J, Abfalterer  W, et al.; Sheffield COVID-19 Genomics Group. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812827.e19. DOIPubMed
  10. Ou  X, Liu  Y, Lei  X, Li  P, Mi  D, Ren  L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620. DOIPubMed
  11. Bartolini  B, Rueca  M, Gruber  CEM, Messina  F, Carletti  F, Giombini  E, et al. SARS-CoV-2 Phylogenetic analysis, Lazio region, Italy, February–March 2020. Emerg Infect Dis J. 2020;26:1842–5. DOIPubMed
  12. Lu  J, du Plessis  L, Liu  Z, Hill  V, Kang  M, Lin  H, et al. Genomic epidemiology of SARS-CoV-2 in Guangdong province, China. Cell. 2020;181:997–1003. DOIPubMed
  13. de Souza  WM, Buss  LF, Candido  DDS, Carrera  J-P, Li  S, Zarebski  AE, et al. Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nat Hum Behav. 2020;4:85665. DOIPubMed
  14. Bedford  T, Greninger  AL, Roychoudhury  P, Starita  LM, Famulare  M, Huang  M-L, et al. Cryptic transmission of SARS-CoV-2 in Washington state. Science. 2020;370:571–5. DOIPubMed
  15. Deng  X, Gu  W, Federman  S, du Plessis  L, Pybus  OG, Faria  NR, et al. Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California. Science. 2020;369:5827. DOIPubMed




Cite This Article

DOI: 10.3201/eid2702.203767

Original Publication Date: January 23, 2021

1These first authors contributed equally to this article. 
2These senior authors contributed equally to this article. 
3Members of the team are listed in Appendix 1 Table 1.

Table of Contents – Volume 27, Number 2—February 2021


Please use the form below to submit correspondence to the authors or contact them at the following address:

Alexander Augusto Martinez Caballero or Sandra Lopez-Verges, Gorgas Memorial Institute of Health Studies, Justo Arosemena Avenue and Street 35th, Panama 0816-02593, Panama

Send To

10000 character(s) remaining.


Page created: November 09, 2020
Page updated: January 23, 2021
Page reviewed: January 23, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.